Teleflex (NYSE:TFX) Issues FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 6.900-7.200 for the period, compared to the consensus earnings per share estimate of 6.700. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Teleflex Stock Down 2.1%

Shares of TFX opened at $137.18 on Thursday. The company’s 50-day simple moving average is $131.41 and its 200-day simple moving average is $122.20. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. Teleflex has a 1 year low of $100.18 and a 1 year high of $144.19. The stock has a market capitalization of $6.07 billion, a PE ratio of -6.02, a P/E/G ratio of 1.04 and a beta of 0.81.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Analysts forecast that Teleflex will post 6.7 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, May 22nd. Teleflex’s dividend payout ratio (DPR) is -5.96%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TFX shares. Wall Street Zen downgraded Teleflex from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $160.00 in a research note on Monday, June 8th. BMO Capital Markets assumed coverage on shares of Teleflex in a research report on Wednesday, July 8th. They set an “outperform” rating and a $159.00 target price on the stock. Needham & Company LLC upped their price target on shares of Teleflex from $147.00 to $159.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Bank of America raised shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $148.90.

Institutional Trading of Teleflex

Several hedge funds have recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in Teleflex by 478.1% in the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock valued at $287,603,000 after acquiring an additional 1,956,811 shares during the period. State Street Corp boosted its holdings in Teleflex by 1.5% during the fourth quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock worth $180,470,000 after buying an additional 22,111 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Teleflex by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after buying an additional 5,051 shares in the last quarter. Abrams Bison Investments LLC increased its holdings in Teleflex by 5.6% in the fourth quarter. Abrams Bison Investments LLC now owns 969,000 shares of the medical technology company’s stock valued at $118,257,000 after buying an additional 51,075 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. lifted its position in shares of Teleflex by 21.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock valued at $85,056,000 after acquiring an additional 122,481 shares during the period. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.